iOnctura Receives €17.5M Funding from the EIC Accelerator

iOnctura BV

iOnctura BV, an Amsterdam, Netherlands-based clinical-stage biotech developing cancer therapies, raised €17.5M in funding.

EIC Accelerator provided the financing, which consisted of:

  • a grant of EUR2.5M, and 
  • EUR15M of equity investment.

The company intends to use the funds to advance its clinical program for IOA-289, an autotaxin inhibitor for the treatment of cancer.

Led by CEO Catherine Pickering, iOnctura is a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways such as cellular proliferation; escape from immune detection; and drug resistance. The company has progressed two therapeutic candidates into mid-stage clinical development: 

  • IOA-244, a highly selective allosteric inhibitor of PI3Kδ; and 
  • IOA-289, a highly-selective, non-competitive autotaxin (ATX) inhibitor.

On 8 December 2022, iOnctura announced the first patient was dosed in a Phase Ib clinical trial of IOA-289 in metastatic pancreatic cancer.

FinSMEs

21/12/2022